GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Purchase Of Investment

Chimeric Therapeutics (ASX:CHM) Purchase Of Investment : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Purchase Of Investment?

Chimeric Therapeutics's purchase of investment for the six months ended in Dec. 2023 was A$0.00 Mil. It means Chimeric Therapeutics spent A$0.00 Mil on purchasing investments. Chimeric Therapeutics's purchase of investment for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Compared with last quarter (A$0.00 Mil in Jun. 2023 ), Chimeric Therapeutics spent the same money on purchasing investments in Dec. 2023 (A$0.00 Mil).


Chimeric Therapeutics Purchase Of Investment Historical Data

The historical data trend for Chimeric Therapeutics's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Purchase Of Investment Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Purchase Of Investment
- -0.04 -

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Purchase Of Investment Get a 7-Day Free Trial - - - - -

Chimeric Therapeutics Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimeric Therapeutics Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimeric Therapeutics (ASX:CHM) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines